Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Unigestion Holding SA

Unigestion Holding SA grew its stake in Merck & Co., Inc. (NYSE:MRK) by 8.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 162,591 shares of the company’s stock after buying an additional 12,679 shares during the quarter. Unigestion Holding SA’s holdings in Merck & Co., Inc. were worth $13,686,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of MRK. Nuveen Asset Management LLC lifted its holdings in shares of Merck & Co., Inc. by 6,517.4% in the 2nd quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock valued at $2,038,169,000 after buying an additional 23,940,007 shares during the period. BlackRock Inc. raised its holdings in Merck & Co., Inc. by 2.3% in the 2nd quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock worth $16,087,745,000 after purchasing an additional 4,397,580 shares during the period. Invesco Ltd. raised its holdings in Merck & Co., Inc. by 18.4% in the 2nd quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock worth $1,535,222,000 after purchasing an additional 2,843,458 shares during the period. Schroder Investment Management Group raised its holdings in Merck & Co., Inc. by 67.7% in the 2nd quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock worth $535,075,000 after purchasing an additional 2,576,060 shares during the period. Finally, UBS Asset Management Americas Inc. raised its holdings in Merck & Co., Inc. by 20.4% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 11,661,412 shares of the company’s stock worth $977,809,000 after purchasing an additional 1,972,587 shares during the period. 74.95% of the stock is owned by institutional investors and hedge funds.

NYSE:MRK traded up $0.71 during trading hours on Friday, hitting $83.59. 6,348,084 shares of the stock were exchanged, compared to its average volume of 10,105,755. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $87.35. The firm’s fifty day moving average price is $84.03 and its 200 day moving average price is $82.71. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 0.82. The company has a market cap of $212.31 billion, a P/E ratio of 19.26, a P/E/G ratio of 1.80 and a beta of 0.54.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 47.94% and a net margin of 20.26%. The company had revenue of $12.40 billion during the quarter, compared to analyst estimates of $11.59 billion. During the same period in the previous year, the business earned $1.19 EPS. Merck & Co., Inc.’s quarterly revenue was up 14.9% on a year-over-year basis. Equities analysts expect that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.

A number of equities analysts recently weighed in on MRK shares. Bank of America started coverage on Merck & Co., Inc. in a report on Wednesday, October 16th. They issued a “neutral” rating and a $90.00 price target for the company. Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 price target on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. JPMorgan Chase & Co. set a $96.00 price target on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, October 10th. Argus upped their price target on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Leerink Swann started coverage on Merck & Co., Inc. in a report on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price target for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $95.13.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

See Also: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply